vs
Side-by-side financial comparison of Brightstar Lottery PLC (BRSL) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $2.5B, roughly 1.9× Brightstar Lottery PLC). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 5.9%, a 4.4% gap on every dollar of revenue. TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $-415.0M).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
BRSL vs TEVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $4.7B |
| Net Profit | $147.0M | $481.0M |
| Gross Margin | — | 56.4% |
| Operating Margin | 11.9% | 6.4% |
| Net Margin | 5.9% | 10.2% |
| Revenue YoY | — | 11.4% |
| Net Profit YoY | — | 321.7% |
| EPS (diluted) | $0.74 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5B | $4.7B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.2B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.2B | ||
| Q1 24 | — | $3.8B |
| Q4 25 | $147.0M | $481.0M | ||
| Q3 25 | — | $433.0M | ||
| Q2 25 | — | $282.0M | ||
| Q1 25 | — | $214.0M | ||
| Q4 24 | — | $-217.0M | ||
| Q3 24 | — | $-437.0M | ||
| Q2 24 | — | $-846.0M | ||
| Q1 24 | — | $-139.0M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | 11.9% | 6.4% | ||
| Q3 25 | — | 19.7% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | — | -0.7% | ||
| Q3 24 | — | -1.2% | ||
| Q2 24 | — | -0.1% | ||
| Q1 24 | — | -5.7% |
| Q4 25 | 5.9% | 10.2% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 5.5% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | -10.1% | ||
| Q2 24 | — | -20.3% | ||
| Q1 24 | — | -3.6% |
| Q4 25 | $0.74 | $0.42 | ||
| Q3 25 | — | $0.37 | ||
| Q2 25 | — | $0.24 | ||
| Q1 25 | — | $0.18 | ||
| Q4 24 | — | $-0.19 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | — | $-0.75 | ||
| Q1 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $3.6B |
| Total DebtLower is stronger | $4.1B | — |
| Stockholders' EquityBook value | $875.0M | $7.9B |
| Total Assets | $9.2B | $40.7B |
| Debt / EquityLower = less leverage | 4.64× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $3.6B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.3B | ||
| Q1 24 | — | $3.0B |
| Q4 25 | $4.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $875.0M | $7.9B | ||
| Q3 25 | — | $7.3B | ||
| Q2 25 | — | $6.8B | ||
| Q1 25 | — | $6.3B | ||
| Q4 24 | — | $5.4B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $6.4B | ||
| Q1 24 | — | $7.3B |
| Q4 25 | $9.2B | $40.7B | ||
| Q3 25 | — | $39.9B | ||
| Q2 25 | — | $40.1B | ||
| Q1 25 | — | $38.4B | ||
| Q4 24 | — | $39.3B | ||
| Q3 24 | — | $41.8B | ||
| Q2 24 | — | $41.3B | ||
| Q1 24 | — | $42.8B |
| Q4 25 | 4.64× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-99.0M | $1.2B |
| Free Cash FlowOCF − Capex | $-415.0M | $1.0B |
| FCF MarginFCF / Revenue | -16.5% | 21.6% |
| Capex IntensityCapex / Revenue | 12.6% | 3.0% |
| Cash ConversionOCF / Net Profit | -0.67× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-99.0M | $1.2B | ||
| Q3 25 | — | $369.0M | ||
| Q2 25 | — | $227.0M | ||
| Q1 25 | — | $-105.0M | ||
| Q4 24 | — | $575.0M | ||
| Q3 24 | — | $693.0M | ||
| Q2 24 | — | $103.0M | ||
| Q1 24 | — | $-124.0M |
| Q4 25 | $-415.0M | $1.0B | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | — | $131.0M | ||
| Q1 25 | — | $-232.0M | ||
| Q4 24 | — | $446.0M | ||
| Q3 24 | — | $545.0M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $-248.0M |
| Q4 25 | -16.5% | 21.6% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 10.5% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | -6.5% |
| Q4 25 | 12.6% | 3.0% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | -0.67× | 2.41× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRSL
Segment breakdown not available.
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
